Evidence map›Paper›PMID 31803404›Full record

ArticleTherapeutic advances in chronic disease2019

Sildenafil improves exercise capacity in patients with cystic fibrosis: a proof-of-concept clinical trial.

Paula Rodriguez-Miguelez, Haruki Ishii, Nichole Seigler, Reva Crandall, Jeffrey Thomas, Caralee Forseen, Kathleen T McKie, Ryan A Harris

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in chronic disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Paula Rodriguez-MiguelezDepartment of Kinesiology and Health Sciences, Virginia Commonwealth University, Richmond, VA, USA.ORCID https://orcid.org/0000-0003-3582-4483
Haruki IshiiGeorgia Prevention Institute, Department of Population Health Sciences, Augusta University, Augusta GA, USA.
Nichole SeiglerGeorgia Prevention Institute, Department of Population Health Sciences, Augusta University, Augusta GA, USA.
Reva CrandallGeorgia Prevention Institute, Department of Population Health Sciences, Augusta University, Augusta GA, USA.
Jeffrey ThomasGeorgia Prevention Institute, Department of Population Health Sciences, Augusta University, Augusta GA, USA.
Caralee ForseenPulmonary and Critical Care, Department of Medicine, Augusta University, Augusta GA, USA.
Kathleen T McKiePediatric Pulmonology, Department of Pediatrics, Augusta University, Augusta GA, USA.
Ryan A HarrisGeorgia Prevention Institute, Department of Population Health Sciences, Augusta University, 1120 15th Street, HS-1707, Augusta GA 30912, USA.ORCID https://orcid.org/0000-0002-8826-681X
Augusta University · USUniversity of Ulster · GBVirginia Commonwealth University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExercise intolerance is a common phenotype observed in patients with cystic fibrosis (CF). Treatment with sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, has previously been shown to improve exercise capacity (VO

methodsThe present investigation utilized a randomized, double-blind, placebo-controlled, crossover study with an acute dose of either sildenafil (50 mg) or placebo (

resultsA significant increase in VO

conclusionsThis proof-of-concept clinical trial demonstrates that sildenafil treatment can improve exercise capacity in patients with CF and that pulmonary function may play an important role in the effectiveness of treatment. Future investigations of sildenafil treatment in patients with CF are certainly warranted.

Indexed as

clinical trialcystic fibrosisexercise intolerancePDE5 inhibitors

Identifiers

PMID31803404
PMCPMC6876159
OpenAlexW2990996471

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.